Inorganic nitrate can help protect patients against kidney damage caused during coronary angiographic procedures

A five-day course of once-daily inorganic nitrate reduces the risk of a serious complication following a coronary angiogram, in which the dye used causes damage to the kidneys. The clinical trial, led by Queen Mary University of London and funded by Heart Research UK, also showed that the five-day course improves renal outcomes at three months and major adverse cardiac events (MACE) at one year compared to placebo. 

Contrast-induced nephropathy (CIN), also known as contrast associated acute kidney injury (CA-AKI), is an uncommon but serious complication following coronary angiography. Coronary angiography is a commonly used procedure that allows healthcare professionals to examine the blood supply to the heart. A special dye, which is visible on x-rays, is injected into the body and when the dye reaches the coronary arteries, an x-ray is taken. While coronary angiography is safe for most people, some patients are at high-risk of CIN, which is a significant cause of death and critical illness for high-risk patients who have had coronary angiographic procedures. For older people and those with heart failure, chronic kidney disease (CKD) or diabetes with CKD, incidence of CIN can be as high as 55%. CIN can lead to serious consequences for patients - including longer hospital stays, increased need for kidney transplants, recurrent revascularisation procedures, and higher mortality. 

One of the principal mechanisms underlying CIN is thought to be an increase of oxidative stress and the accompanying decrease in levels of protective nitric oxide (NO) in the body. This randomised controlled trial, led by Professor Amrita Ahluwalia at Queen Mary University of London and funded by Heart Research UK, examined whether ingesting inorganic nitrate (NO3-) which becomes nitrite (NO2-) and then NO in the body – could compensate for the loss of NO in the body and help prevent kidney injury in high-risk patients receiving contrast angiography. 

640 patients undergoing angiography for non-ST-elevation Acute Coronary Syndrome (ACS) (NSTE-ACS) at Barts Health NHS Trust took part in the trial, with 319 receiving once daily inorganic nitrate capsules (potassium nitrate) and 321 receiving a placebo capsule (potassium chloride). The study showed that patients receiving inorganic nitrate treatment had significantly reduced CIN rates (9.1%) vs placebo (30.5%), lower rates of procedural myocardial infarction (2.7% vs 12.5%), improved three-month renal function and reduced one-year major adverse cardiac events (MACE) (9.1% vs 18.1%) compared to patients who had received the placebo treatment. These findings together support the concept of NO replacement in the form of a short five –day simple inorganic nitrate capsule as a potential solution to prevent CIN and improve both cardiovascular and kidney outcomes after ACS. 

Professor Amrita Ahluwalia, Dean for Research, Faculty of Medicine and Dentistry at Queen Mary, said: “The current gold-standard treatment for blocked coronary arteries is inserting a stent. To do this the cardiologist needs to be able to see where the artery is blocked and that is why it is necessary to use a dye to allow the artery to be clearly seen on the angiogram. This trial suggests that a simple 5-day regime of low-cost inorganic nitrate capsule eliminates the risk of what were, up till now, unavoidable damaging effects. We hope to confirm these findings in a large multi-centre trial in the near future, but the results of Nitrate-CIN give us hope.”  

Kate Bratt-Farrar, Chief Executive at Heart Research UK, said: “We are pleased to fund this research led by Professor Ahluwalia, which hopes to make changes to coronary angiogram protocols and reduce the risk of serious complications for patients. This will allow healthcare professionals to conduct safer treatments and improve patient wellbeing for those at high-risk of developing complications. 

“It is amazing to see the positive outcome of this breakthrough in cardiac research, which was funded by our Translational Research Programme of grants, aiming to bridge the gap between laboratory-based scientific research and patient care. This study has the potential to save countless lives across the UK.”  

Approximately 250,000 coronary angiograms are carried out in the UK every year. Contrast-induced nephropathy (CIN) is deemed responsible for a third of all hospital-acquired acute kidney injuries. Recent assessments of the occurrence of this complication globally suggest an incidence of 12.8% with an associated mortality in those experiencing CIN of 20.2%. 

ENDS 

NOTES TO EDITORS   

Contact:   

Honey Lucas  

Faculty Communications Officer – Medicine and Dentistry   

Queen Mary University of London   

Email: h.lucas@qmul.ac.uk  or press@qmul.ac.uk 

Paper details:   

Amrita Ahluwalia, et al. “Inorganic nitrate benefits contrast-induced nephropathy after coronary angiography for acute coronary syndromes: the NITRATE-CIN Trial.” Published in European Heart Journal. 

DOI: 10.1093/eurheartj/ehae100 

Available after publication at:  https://academic.oup.com/eurheartj/article-lookup/doi/10.1093/eurheartj/ehae100  

Under strict embargo until 1am GMT on Tuesday 19 March 2024. 

A copy of the paper is available upon request. 

Funding information: Heart Research UK. 

Conflicts of Interest Disclosures: Professor Ahluwalia is a Director of HeartBeet Ltd. 

About Queen Mary   

www.qmul.ac.uk     

At Queen Mary University of London, we believe that a diversity of ideas helps us achieve the previously unthinkable.  

Throughout our history, we’ve fostered social justice and improved lives through academic excellence. And we continue to live and breathe this spirit today, not because it’s simply ‘the right thing to do’ but for what it helps us achieve and the intellectual brilliance it delivers.    

Our reformer heritage informs our conviction that great ideas can and should come from anywhere. It’s an approach that has brought results across the globe, from the communities of east London to the favelas of Rio de Janeiro.    

We continue to embrace diversity of thought and opinion in everything we do, in the belief that when views collide, disciplines interact, and perspectives intersect, truly original thought takes form.   

About Heart Research UK 

Proud to stand out from the crowd, Heart Research UK is the charity dedicated to your heart. They’re confronting heart diseases by investing in pioneering medical research, ground-breaking training and education, and in communities to improve their heart health for themselves. For over 50 years they have driven advancements in the prevention, treatment and cure of heart disease to benefit patients as soon as possible. 

In the last 10 years, Heart Research UK has funded over £14.8m in medical research in hospitals and universities across the UK, as well as £1.3m on innovative community-based lifestyle projects to improve the heart health of the nation. 

They won’t stop until there are no more deaths from heart diseases. 

If you’d like to support Heart Research UK’s vital work into the prevention, treatment and cure of heart disease, please visit www.heartresearch.org.uk for inspiration on how you could help.